

Steve Pascolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8592058/publications.pdf>

Version: 2024-02-01

44
papers

3,151
citations

201658

27
h-index

302107

39
g-index

45
all docs

45
docs citations

45
times ranked

3658
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA-A2.1 ⁺ restricted Education and Cytolytic Activity of CD8 ⁺ T Lymphocytes from β 2-Microglobulin (β 2m) HLA-A2.1 Monochain Transgenic H-2Db β 2m Double Knockout Mice. <i>Journal of Experimental Medicine</i> , 1997, 185, 2043-2051.	8.5	457
2	Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients. <i>Journal of Immunotherapy</i> , 2009, 32, 498-507.	2.4	301
3	Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA. <i>Journal of Immunotherapy</i> , 2008, 31, 180-188.	2.4	216
4	Intradermal Vaccinations With RNA Coding for TAA Generate CD8 ⁺ and CD4 ⁺ Immune Responses and Induce Clinical Benefit in Vaccinated Patients. <i>Molecular Therapy</i> , 2011, 19, 990-999.	8.2	199
5	Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. <i>European Journal of Immunology</i> , 2005, 35, 1557-1566.	2.9	183
6	Immunostimulating capacities of stabilized RNA molecules. <i>European Journal of Immunology</i> , 2004, 34, 537-547.	2.9	128
7	Messenger RNA-based vaccines. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1285-1294.	3.1	127
8	CD141 ⁺ dendritic cells produce prominent amounts of IFN- γ after dsRNA recognition and can be targeted via DEC-205 in humanized mice. <i>Blood</i> , 2013, 121, 5034-5044.	1.4	113
9	Vaccination with Messenger RNA (mRNA). <i>Handbook of Experimental Pharmacology</i> , 2008, , 221-235.	1.8	107
10	Particle size and activation threshold: a new dimension of danger signaling. <i>Blood</i> , 2010, 115, 4533-4541.	1.4	103
11	Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. <i>European Journal of Immunology</i> , 2006, 36, 2807-2816.	2.9	101
12	Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies. <i>European Journal of Pharmacology</i> , 2016, 771, 139-144.	3.5	98
13	Novel multi-peptide vaccination in HlaA2 ⁺ hormone sensitive patients with biochemical relapse of prostate cancer. <i>Prostate</i> , 2009, 69, 917-927.	2.3	97
14	Plasmid DNA- and messenger RNA-based anti-cancer vaccination. <i>Immunology Letters</i> , 2008, 115, 33-42.	2.5	81
15	Promiscuous survivin peptide induces robust CD4 ⁺ T _H 1 cell responses in the majority of vaccinated cancer patients. <i>International Journal of Cancer</i> , 2012, 131, 140-149.	5.1	70
16	Gemcitabine depletes regulatory T _H 1 cells in human and mice and enhances triggering of vaccine-specific cytotoxic T _H 1 cells. <i>International Journal of Cancer</i> , 2011, 129, 832-838.	5.1	69
17	Characterization of the ribonuclease activity on the skin surface. <i>Genetic Vaccines and Therapy</i> , 2006, 4, 4.	1.5	68
18	Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1005-1012.	2.3	61

#	ARTICLE	IF	CITATIONS
19	Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype. <i>Viruses</i> , 2021, 13, 270.	3.3	53
20	Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets. <i>Frontiers in Immunology</i> , 2015, 6, 527.	4.8	47
21	Vaccination With Messenger RNA. , 2006, 127, 23-40.		44
22	Protamine-Based Strategies for RNA Transfection. <i>Pharmaceutics</i> , 2021, 13, 877.	4.5	42
23	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. <i>OncImmunology</i> , 2016, 5, e1108511.	4.6	41
24	HLA class I transgenic mice: development, utilisation and improvement. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 919-938.	3.1	38
25	Blockade of programmed cell death protein 1 (PD-1) in SÃ©zary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. <i>OncImmunology</i> , 2020, 9, 1738797.	4.6	32
26	Charting DENR-dependent translation reinitiation uncovers predictive uORF features and links to circadian timekeeping via Clock. <i>Nucleic Acids Research</i> , 2019, 47, 5193-5209.	14.5	30
27	Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. <i>Genetic Vaccines and Therapy</i> , 2005, 3, 6.	1.5	29
28	The messenger's great message for vaccination. <i>Expert Review of Vaccines</i> , 2015, 14, 153-156.	4.4	28
29	Design of in vitro Transcribed mRNA Vectors for Research and Therapy. <i>Chimia</i> , 2019, 73, 391.	0.6	28
30	Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 325-338.	4.2	27
31	Functional differences between protamine preparations for the transfection of mRNA. <i>Drug Delivery</i> , 2020, 27, 1231-1235.	5.7	26
32	Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in SÃ©zary syndrome. <i>Leukemia and Lymphoma</i> , 2019, 60, 1899-1907.	1.3	23
33	Vaccines against COVID-19: Priority to mRNA-Based Formulations. <i>Cells</i> , 2021, 10, 2716.	4.1	17
34	The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. <i>Vaccine</i> , 2011, 29, 3832-3836.	3.8	16
35	Generation of Immunostimulating 130 nm Protamineâ€“RNA nanoparticles. <i>Methods in Molecular Biology</i> , 2017, 1499, 155-163.	0.9	12
36	Increased Chlormethine-Induced DNA Double-Stranded Breaks in Malignant T Cells from Mycosis Fungoides Skin Lesions. <i>JID Innovations</i> , 2022, 2, 100069.	2.4	10

#	ARTICLE	IF	CITATIONS
37	Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. , 2021, 9, e002932.		7
38	mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma. Pharmaceutics, 2021, 13, 1040.	4.5	7
39	Sensitivity and specificity of T-cell receptor PCR BIOMED-2 clonality analysis for the diagnosis of cutaneous T-cell lymphoma. European Journal of Dermatology, 2020, 30, 12-15.	0.6	7
40	Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in SÅ©zary syndrome. OncoImmunology, 2021, 10, 1873530.	4.6	6
41	Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors. Molecular Therapy, 2022, 30, 1163-1170.	8.2	2
42	Plasmid DNA and Messenger RNA for Therapy. , 0, , 971-1011.		0
43	Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring. Viruses, 2021, 13, 1232.	3.3	0
44	Enhancement of Gene Gun-Induced Vaccine-Specific Cytotoxic T-Cell Response by Administration of Chemotherapeutic Drugs. Methods in Molecular Biology, 2013, 940, 189-198.	0.9	0